Specification Table {#s0005}
===================

TableSubject areaMedicineMore specific subject areaEpidemiology of peripheral arterial diseaseType of dataTables, figuresHow data was acquiredRetrospective analyses of patient filesData formatRaw, analysedExperimental factorsAll cause survival, amputation free survival, TASC II classification and crural index were measuredExperimental featuresRetrospective analyses of DSA images and 36-month patient survival and amputation free survivalData source locationTurku University Hospital, Turku, FinlandData accessibilityData is with this article

Value of the data {#s0010}
=================

•This is the first analyses of correlation between AFS and crural index.•The data demonstrates the challenging nature of extensive crural disease. The more extensive the atherosclerosis on crural vessels is, the more interventions are needed.•Present data shows that in addition to poor survival and AFS, crural index IV is associated with conservative treatment and inability to treat.•It also provides estimation of survival and amputation free survival for TASC II classification for aortoiliac and femoropopliteal segments [@bib2], [@bib3], [@bib4].

1. Data {#s0015}
=======

The presented data is acquired from analysis of amputation free survival and extent of atherosclerosis in crural vessels of PAD patients. Patient cohort was analysed according to widely used classification (TASC II) [@bib2], [@bib3], [@bib4] and a new classification for the crural vessels [@bib1]. The Kaplan-Meier curves for AFS are shown in [Fig. 1](#f0005){ref-type="fig"}A and B. [Table 1](#t0005){ref-type="table"}A--E presents the mean AFS±SE for different classifications of arterial disease and disease level in lower limb arteries. [Table 2](#t0010){ref-type="table"}A--E shows patient survival during 36-month follow-up divided correspondingly to [Table 1](#t0005){ref-type="table"} AFS [Table 3](#t0015){ref-type="table"}.

2. Experimental design, materials and methods {#s0020}
=============================================

The data is based on 887 consecutive patients admitted to the Department of Vascular Surgery at the Turku University Hospital (Turku, Finland) either for diagnostic DSA or for endovascular treatment of PAD from January 1st 2009 to July 30th 2011. All patients were included regardless of earlier PAD history. Deaths and amputations within the patient cohort were registered for the first 36-months, which was the cut-off point for follow-up.

2.1. DSA analysis {#s0025}
-----------------

The index classification was as described in TASC II for aorto-iliac and femoro-popliteal segments. Aorto-iliac and femoro-popliteal segments TASC II classification A--D, (coded as 1--4) were for the statistical analyses. For the crural region, all three vessels were first analysed separately and a Crural Index was formed accordingly (see for further description [@bib1]). In order to assess different vascular segments against each other, each patient was assigned into a specific group of disease localisation: 1) aorto-iliac, 2) femoro-popliteal or 3) crural, based on which 0--IV rating gave the highest number.

2.2. Statistical analyses {#s0030}
-------------------------

All statistical analyses were performed using the IBM SPSS version 22 statistics program. Continuous variables were expressed as mean±standard error (SE). Survival analyses were assessed by Kaplan--Meier curves and Log-rank statistics.

Appendix A. Transparency document {#s0045}
=================================

Supplementary material

Present study was supported by an EVO grant, Turku University Hospital.

Transparency data associated with this article can be found in the online version at [doi:10.1016/j.dib.2016.05.039](http://dx.doi.org/10.1016/j.dib.2016.05.039){#ir0005}.

![A**.** Kaplan-Meier curves show the cumulative amputation free survival (AFS) during 36-months follow-up. Separate curves for Crural Index I--IV and for patients with no detectable significant atherosclerotic lesion in crural arterial vessels. The survival curve of Crural Index IV demonstrates the poor prognosis of patients with extensive atherosclerosis in crural arteries. Numbers at risk for each curve marked at defined time-point. B**.** Kaplan--Meier curves demonstrating amputation free survival based on most severely diseased vascular segments. A more detailed presentation of data analysis is given in the methods section. The segments are marked as aorto-iliac (AI), femoro-popliteal (FP) and crural (Cr). Severe crural lesions result predict a poor AFS. Numbers at risk for each curve marked at defined time-point.](gr1){#f0005}

###### 

The analyses of treatments in each Crural index group. Unable to treat percentage of cases not being able to treat either for the technical reasons or patient unfit for demanded surgery. Conservative includes unable to treat and patients with claudication and requiring too extensive revascularisation procedures for clinical symptom. Endovascular procedures during 36-months follow-up to the initially worse leg. Surgical revascularisations to initially worse leg during 36-months follow-up. Treatments to the initially worse leg during 36-month follow-up, including both endovascular and surgical procedures. Amputation free survival (AFS) 1, 2 and 3 years.

  ---------------------- --------------- --------------- --------------- --------------- ---------------
  A                                                                                      
  Crural Index           Grade 0         Grade I         Grade II        Grade III       Grade IV
                                                                                         
  Unable to treat        3.20%           11%             4.30%           5.20%           9.60%
  Conservative           7.1%            20%             16%             18%             31%
  Endovascular           54%             67%             65%             62%             49%
  Surgery                49%             23%             30%             39%             32%
  Treatments (mean±SE)   1.3±0.086       1.06±1.102      1.10±0.047      1.31±0.068      0.098±0.073
  AFS 1, 2, 3 years      87%, 81%, 79%   77%, 76%, 73%   79%, 74%, 74%   67%, 60%, 58%   49%, 40%, 37%
  ---------------------- --------------- --------------- --------------- --------------- ---------------

  ---------------------- --------------- ------------------ ---------------
                                                            
  B                                                         
  Most severe segment    Aorto-iliac     Femoro-popliteal   Crural
                                                            
  Unable to treat        2.10%           0.10%              14%
  Conservative           7%              12%                31%
  Endovascular           65%             61%                56%
  Surgery                43%             44%                21%
  Treatments (mean±SE)   1.28±0.072      1.36±0.052         0.89±0.045
  AFS 1, 2, 3 years      86%, 79%, 78%   80%, 75%, 74%      51%, 44%, 41%
  ---------------------- --------------- ------------------ ---------------

###### 

Mean estimated amputation free survival during 36-months follow-up, SE and 95% CI presented in the table for A) Aorto-iliac (AI), B) Femoro-popliteal (FP), C) Crural (Cr) grades I--IV, D) Localization of significant atherosclerotic lesion, E) The most severe atherosclerotic segment. Log-rank test shown on the left row of the table. Number of patients at risk for each group *n*.

Table 2.

  ------------ ---------- ------- ---------------- ---------------------------
                          (*n*)   Mean months±SE   95% CI; Lower−Upper Bound
                                                   
  A            AI I       92      32.1±1.06        30.1−34.2
               AI II      57      31.2±1.58        28.1−34.3
               AIII       34      27.6±2.27        23.1−32.0
  *P*=0.010    AIIV       65      28.5±1.59        25.4−31.6
                                                     
  B            FP I       82      28.6±1.60        25.5±29.4
               FP II      140     29.2±1.09        27.0±31.3
               FP III     114     28.2±1.22        25.8±30.6
  *p*=0.335    FP IV      329     27.3±0.758       25.8±28.8
                                                     
  C            Cr I       70      30.4±1.50        27.5−33.4
               Cr III     235     30.7±0.772       29.2−32.2
               Cr III     289     26.7±0.835       25.1−28.4
  *P*\<0.001   Cr IV      166     21.0±1.17        18.7−23.3
                                                     
  D            AI         25      36.5±0.47        35.6−37.4
               FP         61      32.7±1.30        30.2−35.3
               Cr         144     24.3±1.24        21.9−26.8
               AI+FP      36      32.6±1.48        29.7−35.5
               AI+Cr      48      33.0±1.45        30.2−35.8
               FP+Cr      428     27.0±0.685       25.7−28.4
  *P*\<0.001   AI+FP+Cr   138     27.7±1.14        25.4−29.9
                                                     
  E            AI         140     32.5±0.849       30.8−34.1
               FP         417     31.2±0.565       30.0−32.3
  *P*\<0.001   Cr         325     21.8±0.844       20.2−23.5
               Overall            27.9±0.460       27.0−28.8
                                                   
  ------------ ---------- ------- ---------------- ---------------------------

###### 

Mean estimated survival during 36-months follow-up, SE and 95% CI presented in the table for A) Aorto-iliac (AI), B) Femoro-popliteal (FP), C) Crural (Cr) grades I--IV, D) Localization of significant atherosclerotic lesion, E) The most severe atherosclerotic segment. Log-rank test shown on the left row of the table. Number of patients at risk for each group *n*.

Table 3.

  ------------------------------------------------------------------ ---------- --------- ---------------- ---------------------------
                                                                                \(n\)     Mean Months±SE   95% CI; Lower-Upper Bound
                                                                                                           
  A                                                                  AI I       \(92\)    32.4±1.01        30.5−34.4
                                                                     AI II      \(57\)    31.5±1.52        28.5−34.5
                                                                     AI III     \(34\)    27.6±2.31        23.0−32.1
  *P*=0.128                                                          AI IV      \(66\)    31.0±1.36        28.4−33.7
                                                                                                             
  B                                                                  FP I       \(82\)    29.7±1.52        26.7−32.7
                                                                     FP II      \(140\)   29.9±1.05        27.8−31.9
                                                                     FP III     \(114\)   28.9±1.19        26.5−31.2
  *P*=0.247                                                          FP IV      \(330\)   28.8±0.700       27.4−30.2
                                                                                                             
  C                                                                  Cr I       \(70\)    31.4±1.38        28.7−34.1
                                                                     Cr II      \(235\)   31.4±0.710       30.0−32.8
                                                                     Cr III     \(289\)   28.4±0.789       26.8−29.9
  *P*=0.000                                                          Cr IV      \(167\)   23.2±1.14        20.9−25.4
                                                                                                             
  D                                                                  AI         \(25\)    36.2±0.48        35.6−37.5
                                                                     FP         \(61\)    32.8±1.26        30.3−35.3
                                                                     Cr         \(144\)   26.6±1.15        24.4−28.9
                                                                     AI+FP      \(36\)    33.3±1.43        30.5−36.1
                                                                     AI+Cr      \(48\)    33.3±1.40        30.5−36.0
                                                                     FP+Cr      \(429\)   28.4±0.648       27.1−29.6
  *P*=0.030                                                          AI+FP+Cr   \(139\)   28.9±1.06        26.8−31.0
                                                                                                             
  E                                                                  AI         \(141\)   33.7±0.713       32.3−35.1
                                                                     FP         \(416\)   31.9±0.530       30.8−32.9
  *P*=0.000                                                          Cr         \(325\)   23.8±0.813       22.2−25.3
                                                                     Overall              29.2±0.430       28.3−30.0
                                                                                                           
  ^a^ Estimation is limited to the largest survival time 37 months                                         
  ------------------------------------------------------------------ ---------- --------- ---------------- ---------------------------
